7/21/2009

Novartis secured FDA clearance to market its Tekturna HCT combination treatment for patients with high blood pressure who do not respond to a standalone therapy. The medicine contains the diuretic hydrochlorothiazide, a common regimen for hypertension.

Full Story:
Reuters

Related Summaries